Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Spectrum Pharma Inc
(NQ:
SPPI
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 31, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Spectrum Pharma Inc
< Previous
1
2
3
4
5
6
7
8
Next >
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in First Filed Securities Class Action Initiated by the Firm– SPPI
January 02, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
December 27, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
December 17, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
SPPI EQUITY NOTICE: Rosen Law Firm Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI
December 12, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
Spectrum Pharmaceuticals, Inc. (SPPI) Shareholder Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc.
December 12, 2022
From
Robbins LLP
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
December 07, 2022
From
The Schall Law Firm
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Spectrum Pharmaceuticals, Inc. (SPPI)
December 06, 2022
From
Robbins LLP
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action on Behalf of Investors in Spectrum Pharmaceuticals, Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm
December 06, 2022
From
The Schall Law Firm
Via
Business Wire
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
December 06, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
December 05, 2022
From
Spectrum Pharmaceuticals
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and Fox and Encourages Investors to Contact the Firm
December 02, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, Cantaloupe, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
November 27, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection
November 25, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, Cantaloupe, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
November 16, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
November 06, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update
November 03, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Spectrum Pharmaceuticals, Inc. Investors to Inquire About Class Action Investigation – SPPI
October 28, 2022
From
Rosen Law Firm
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and UiPath and Encourages Investors to Contact the Firm
October 21, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection
October 21, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm
October 16, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm
October 11, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, Compass, and Spectrum and Encourages Investors to Contact the Firm
October 02, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
SPECTRUM ALERT: Bragar Eagel & Squire, P.C. is Investigating Spectrum Pharmaceuticals, Inc. on Behalf of Spectrum Stockholders and Encourages Investors to Contact the Firm
September 29, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
September 23, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting
September 22, 2022
From
Spectrum Pharmaceuticals
Via
Business Wire
Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022
September 10, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
SPECTRUM PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Spectrum Pharmaceuticals, Inc. - SPPI
September 09, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection
September 09, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022
September 05, 2022
From
Spectrum Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.